7H2

(0)No Reviews yet
$50.00
QuantityPrice
1 – 19$50.00
20 – 49$35.00
50 – 99$32.00
100 +$30.00
SKU: 7H2-s

In Stock

Available: 35

DSHB Data Sheet
Back

Catalog Fields

Clone ID/Product Name: 7H2
Available to For-Profits: Yes
Alternate Antibody Name:
Gene Symbol: ITGB3
Ab Isotype: MIgG1
Gene Name:
Antibody Registry ID: AB_2617394 
Uniprot ID: P05106 
RRID:  
Entrez Gene ID: 3690 
Clonality: Monoclonal
Immunogen: Human platelets
Clone:
Immunogen Sequence: Full length protein
Myeloma Strain: X63-Ag8.653
Epitope Mapped: Yes
Antigen Name: integrin beta-3 (CD61), human
Epitope Location or Sequence: integrin beta3 PSI domain
Alternate Antigen Name:
Deposit Date: 5/2/2013
Antigen Molecular Weight: Predicted; 87 kDa; Apparent: 90 kDa
Depositor: Coller, B.S.
Antigen Sequence:
Depositor Institution: Rockefeller University
Antigen Species: Human
Depositor Notes: 7H2 reacts with alphaIIbbeta3 complex on platelets and has variable effects on platelet function. The epitope recognized by 7H2 is located on the beta3 PSI domain (unpublished mutational analysis).
Host Species: mouse
Hybridoma Cells Available (Non-Profit): No
Confirmed Species Reactivity: Human, Primate
Additional Information: 7H2 recognizes free beta3 as weel as alphaVbeta3 and alphaIIbbeta3 and their pro-forms. In immunoblots, 7H2 doesn't recognize its target under reducing conditions.
Predicted Species Reactivity:  
Human Protein Atlas:  
Additional Characterization:  
Recommended Applications: FACS, Function Blocking, Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Western Blot
All cell products contain the antimicrobial ProClin. Click here for additional information.
These hybridomas were created by your colleagues. Please acknowledge the hybridoma contributor and the Developmental Studies Hybridoma Bank (DSHB) in the Materials and Methods of your publications. Please email the citation to us.
For your Materials & Methods section:
7H2 was deposited to the DSHB by Coller, B.S. (DSHB Hybridoma Product 7H2)
Storage and Handling Recommendations
Although many cell products are maintained at 4°C for years without loss of activity, shelf-life at 4°C is highly variable. For immediate use, short term storage at 4°C up to two weeks is recommended. For long term storage, divide the solution into volumes of no less than 20 ul for freezing at -20°C or -80°C. The small volume aliquot should provide sufficient reagent for short term use. Freeze-thaw cycles should be avoided. For concentrate or bioreactor products, an equal volume of glycerol, a cryoprotectant, may be added prior to freezing.
Usage Recommendations
The optimal Ig concentration for an application varies by species and antibody affinity. For each product, the antibody titer must be optimized for every application by the end user laboratory. A good starting concentration for immunohistochemistry (IHC), immunofluorescence (IF), and immunocytochemistry (ICC) when using mouse Ig is 2-5 ug/ml. For western blots, the recommended concentration range of mouse Ig 0.2-0.5 ug/ml. In general, rabbit antibodies demonstrate greater affinity and are used at a magnitude lower Ig concentration for initial testing. The recommended concentrations for rabbit Ig are 0.2-0.5 ug/ml (IF, IHC and ICC) and 20-50 ng/ml (WB).

14 References

  • Initial Publication
  • IF References
  • WB References
  • IHC References
  • IP References
  • FB References
  • FACS References
  • Epitope Map References
  • All References
    • Initial Publication

    Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: requirement for antibody bivalency.
    Coller BS
    Thrombosis and haemostasis 72.6 (1994 Dec): 964-72.

    IF References

    Swing-out of the β3 hybrid domain is required for αIIbβ3 priming and normal cytoskeletal reorganization, but not adhesion to immobilized fibrinogen.
    Coller BS
    PloS one 8.12 (2013): e81609.

    Ligand density dramatically affects integrin alpha IIb beta 3-mediated platelet signaling and spreading.
    Coller BS
    Blood 109.12 (2007 Jun 15): 5260-9.

    Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen.
    Coller BS
    Blood 111.3 (2008 Feb 1): 1248-56.

    WB References

    Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: requirement for antibody bivalency.
    Coller BS
    Thrombosis and haemostasis 72.6 (1994 Dec): 964-72.

    Glycoprotein IIb Leu214Pro mutation produces glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa.
    French DL
    Blood 91.5 (1998 Mar 1): 1562-71.

    Swing-out of the β3 hybrid domain is required for αIIbβ3 priming and normal cytoskeletal reorganization, but not adhesion to immobilized fibrinogen.
    Coller BS
    PloS one 8.12 (2013): e81609.

    A naturally occurring mutation near the amino terminus of alphaIIb defines a new region involved in ligand binding to alphaIIbbeta3.
    Poncz M
    Blood 95.1 (2000 Jan 1): 180-8.

    A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann's thrombasthenia.
    French DL
    Blood 88.5 (1996 Sep 1): 1666-75.

    Two novel mutations in the alpha IIb calcium-binding domains identify hydrophobic regions essential for alpha IIbbeta 3 biogenesis.
    French DL
    Blood 101.6 (2003 Mar 15): 2268-76.

    IHC References

    Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
    Marmur JD
    Arteriosclerosis, thrombosis, and vascular biology 18.8 (1998 Aug): 1342-9.

    IP References

    Glycoprotein IIb Leu214Pro mutation produces glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa.
    French DL
    Blood 91.5 (1998 Mar 1): 1562-71.

    Mapping early conformational changes in alphaIIb and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting its bent conformation.
    Coller BS
    Blood 109.9 (2007 May 1): 3725-32.

    Three novel beta-propeller mutations causing Glanzmann thrombasthenia result in production of normally stable pro-alphaIIb, but variably impaired progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi.
    Coller BS
    Journal of thrombosis and haemostasis : JTH 3.12 (2005 Dec): 2773-83.

    FB References

    Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: requirement for antibody bivalency.
    Coller BS
    Thrombosis and haemostasis 72.6 (1994 Dec): 964-72.

    Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
    Coller BS
    The Journal of clinical investigation 98.3 (1996 Aug 1): 863-74.

    FACS References

    Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: requirement for antibody bivalency.
    Coller BS
    Thrombosis and haemostasis 72.6 (1994 Dec): 964-72.

    Functional and computational studies of the ligand-associated metal binding site of beta3 integrins.
    Filizola M
    Proteins 71.4 (2008 Jun): 1779-91.

    Epitope Map References

    Three-dimensional reconstruction of intact human integrin αIIbβ3: new implications for activation-dependent ligand binding.
    Coller BS
    Blood 122.26 (2013 Dec 19): 4165-71.

    All References

    Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
    Marmur JD
    Arteriosclerosis, thrombosis, and vascular biology 18.8 (1998 Aug): 1342-9.

    Swing-out of the β3 hybrid domain is required for αIIbβ3 priming and normal cytoskeletal reorganization, but not adhesion to immobilized fibrinogen.
    Coller BS
    PloS one 8.12 (2013): e81609.

    Ligand density dramatically affects integrin alpha IIb beta 3-mediated platelet signaling and spreading.
    Coller BS
    Blood 109.12 (2007 Jun 15): 5260-9.

    Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen.
    Coller BS
    Blood 111.3 (2008 Feb 1): 1248-56.

    Partial inhibition of platelet aggregation and fibrinogen binding by a murine monoclonal antibody to GPIIIa: requirement for antibody bivalency.
    Coller BS
    Thrombosis and haemostasis 72.6 (1994 Dec): 964-72.

    Glycoprotein IIb Leu214Pro mutation produces glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa.
    French DL
    Blood 91.5 (1998 Mar 1): 1562-71.

    A naturally occurring mutation near the amino terminus of alphaIIb defines a new region involved in ligand binding to alphaIIbbeta3.
    Poncz M
    Blood 95.1 (2000 Jan 1): 180-8.

    A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann's thrombasthenia.
    French DL
    Blood 88.5 (1996 Sep 1): 1666-75.

    Two novel mutations in the alpha IIb calcium-binding domains identify hydrophobic regions essential for alpha IIbbeta 3 biogenesis.
    French DL
    Blood 101.6 (2003 Mar 15): 2268-76.

    Mapping early conformational changes in alphaIIb and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting its bent conformation.
    Coller BS
    Blood 109.9 (2007 May 1): 3725-32.

    Three novel beta-propeller mutations causing Glanzmann thrombasthenia result in production of normally stable pro-alphaIIb, but variably impaired progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi.
    Coller BS
    Journal of thrombosis and haemostasis : JTH 3.12 (2005 Dec): 2773-83.

    Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
    Coller BS
    The Journal of clinical investigation 98.3 (1996 Aug 1): 863-74.

    Functional and computational studies of the ligand-associated metal binding site of beta3 integrins.
    Filizola M
    Proteins 71.4 (2008 Jun): 1779-91.

    Three-dimensional reconstruction of intact human integrin αIIbβ3: new implications for activation-dependent ligand binding.
    Coller BS
    Blood 122.26 (2013 Dec 19): 4165-71.

    Back

    Ratings & Reviews

    No reviews available

    Be the first to Write a Review